This excerpt taken from the SNY 6-K filed Nov 28, 2008.
all Clinical Trials with rimonabant
Paris, November 5, 2008 - Sanofi-aventis announced today that it has decided to discontinue the ongoing rimonabant clinical development program in all indications.
Todays company decision has been taken in light of recent demands by certain national health authorities. As a result the feasibility of the global clinical development program has been compromised.
Sanofi-aventis will inform Health Care Professionals as of today. Persons currently enrolled in these clinical trials should consult their clinical investigator to discuss their treatment.
This announcement does not change the Companys guidance for 2008.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com.